PG
Highly rated in
32
conditions

Dr. Pierre M. Giglio

Ohio State Brain And Spine Hospital
Columbus, OH
Highly rated in
32
conditions
Specialties:Neurology
Experience:30 Years
Clinical Trials:Currently Recruiting for 3 Trials
Accepts:New PatientsMedicare
Highly rated in
32
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Pierre M. Giglio's experience treating your condition:
About Dr. Pierre M. Giglio

Pierre Giglio is a Neurologist in Columbus, Ohio. Giglio has been practicing medicine for over 30 years and is highly rated in 32 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. He is licensed to treat patients in Ohio. Giglio is currently accepting new patients.

His clinical research consists of co-authoring 59 peer reviewed articles and participating in 12 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Pierre M. Giglio it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Pierre M. Giglio accepts the following insurance:

  •  Ambetter
  •  Molina Healthcare
  •  CareSource
  •  Buckeye Health
Call to see if your plan is accepted.
Locations
300 W 10th Ave, Columbus, OH 43210
Background & Education
Graduate Institution
Other, 1993
Specialties
Neurology
Licenses
Psychiatry & Neurology in OH
Hospital Affiliations
Ohio State University Brain And Spine Hospital
The James Cancer Hospital And Solove Research Institute
Ohio State University Wexner Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: TemozolomideLomustineRegorafenibPaxalisibVAL-083
Study Phase: Phase 2/Phase 3
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 27, 2022
Intervention Type: Drug
Study Drugs: VismodegibGSK2256098CapivasertibAbemaciclib
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Recruiting
Publish Date: March 24, 2022
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ)ProcarbazineAdjuvant Temozolomide (TMZ)CCNUVincristine
Study Phase: Phase 3
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Enrollment Status: Active, not recruiting
Publish Date: September 28, 2022
Intervention Type: Drug, Radiation
Study Drugs: BMX-001Temozolomide
Study Phase: Phase 2
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Enrollment Status: Suspended
Publish Date: July 20, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Trial of AZD9291 (Osimertinib) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active, not recruiting
Publish Date: July 06, 2022
Intervention Type: Drug, Other, Biological
Study Drugs: BevacizumabOsimertinib
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Enrollment Status: Active, not recruiting
Publish Date: June 30, 2022
Intervention Type: Drug, Biological
Study Drugs: BevacizumabCediranibCediranib MaleateOlaparib
Study Phase: Phase 2
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Active, not recruiting
Publish Date: August 18, 2021
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96Bevacizumab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: August 13, 2018
Intervention Type: Biological
Study Phase: Phase 3
The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma
Enrollment Status: Withdrawn
Publish Date: January 31, 2018
Intervention Type: Procedure, Drug, Other
Study Phase: Not Applicable
Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen
Enrollment Status: Terminated
Publish Date: January 31, 2018
Intervention Type: Drug
Study Phase: Phase 2
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease
Enrollment Status: Completed
Publish Date: April 13, 2015
Intervention Type: Radiation
View 9 Less Clinical Trials -
59 Total Publications
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma.
Journal: Biomedicines
Published: June 29, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
JM
Dr. Jerry R. Mendell
Neurology
Highly rated in
30
conditions
Neurology

Nationwide Childrens

Westerville Surgery Center

455 Executive Campus Dr, 
Westerville, OH 
 10.5 mi

Dr. Jerry Mendell, MD is a Neurology Specialist in Columbus, OH and has over 56 years of experience in the medical field. He graduated from University of Texas Southwestern Medical School in 1966.

JK
Dr. John T. Kissel
Neurology
Highly rated in
34
conditions
Neurology

Martha Morehouse Outpatient Care

2050 Kenny Rd, 
Columbus, OH 
 1.1 mi

John Kissel is a Neurologist in Columbus, Ohio. Kissel has been practicing medicine for over 45 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 1, and Paramyotonia Congenita. He is licensed to treat patients in Ohio. Kissel is currently accepting new patients.

AP
Dr. Anup D. Patel
Neurology | Child Neurology
Highly rated in
14
conditions
Neurology
Child Neurology

Nationwide Childrens

Nationwide Childrens Hospital

700 Childrens Dr, 
Columbus, OH 
 3.5 mi

Anup Patel is a Neurologist and a Child Neurologist in Columbus, Ohio. Patel has been practicing medicine for over 23 years and is highly rated in 14 conditions, according to our data. His top areas of expertise are Epilepsy, Seizures, Spasmus Nutans, Prostatectomy, and Endoscopy. He is licensed to treat patients in Indiana. Patel is currently accepting new patients.